Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel Free BIO.B Stock Alerts

Bio-Rad Laboratories (BIO.B) Competitors

Bio-Rad Laboratories logo
$365.08 0.00 (0.00%)
As of 09/4/2026
Compare

BIO.B vs. ILMN, MTD, MEDP, RVTY, and CRL

Should you buy Bio-Rad Laboratories stock or one of its competitors? Bio-Rad Laboratories's main competitors and comparable companies include Illumina (ILMN), Mettler-Toledo International (MTD), Medpace (MEDP), Revvity (RVTY), and Charles River Laboratories International (CRL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bio-Rad Laboratories compare to Illumina?

Bio-Rad Laboratories (NYSE:BIO.B) and Illumina (NASDAQ:ILMN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Illumina has a net margin of 18.36% compared to Bio-Rad Laboratories' net margin of 8.59%. Illumina's return on equity of 29.84% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories8.59% 3.54% 2.48%
Illumina 18.36%29.84%12.17%

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 2.9% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Illumina has higher revenue and earnings than Bio-Rad Laboratories. Illumina is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.78$759.90M$8.2544.25
Illumina$4.34B7.59$850M$5.3640.71

Bio-Rad Laboratories has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Illumina has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Illumina has a consensus price target of $191.31, suggesting a potential downside of 12.33%. Given Illumina's stronger consensus rating and higher probable upside, analysts clearly believe Illumina is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Illumina
2 Sell rating(s)
7 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.39

In the previous week, Illumina had 38 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 38 mentions for Illumina and 0 mentions for Bio-Rad Laboratories. Illumina's average media sentiment score of 0.88 beat Bio-Rad Laboratories' score of 0.00 indicating that Illumina is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Illumina Positive

Summary

Illumina beats Bio-Rad Laboratories on 13 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Mettler-Toledo International?

Bio-Rad Laboratories (NYSE:BIO.B) and Mettler-Toledo International (NYSE:MTD) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.7% of Mettler-Toledo International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bio-Rad Laboratories has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

In the previous week, Mettler-Toledo International had 25 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 25 mentions for Mettler-Toledo International and 0 mentions for Bio-Rad Laboratories. Mettler-Toledo International's average media sentiment score of 1.14 beat Bio-Rad Laboratories' score of 0.00 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Mettler-Toledo International Positive

Mettler-Toledo International has a net margin of 21.91% compared to Bio-Rad Laboratories' net margin of 8.59%. Bio-Rad Laboratories' return on equity of 3.54% beat Mettler-Toledo International's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories8.59% 3.54% 2.48%
Mettler-Toledo International 21.91%-1,212.14%25.11%

Mettler-Toledo International has a consensus target price of $1,445.31, indicating a potential upside of 7.47%. Given Mettler-Toledo International's stronger consensus rating and higher probable upside, analysts clearly believe Mettler-Toledo International is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Mettler-Toledo International
1 Sell rating(s)
8 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.33

Mettler-Toledo International has higher revenue and earnings than Bio-Rad Laboratories. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.78$759.90M$8.2544.25
Mettler-Toledo International$4.13B6.52$869.19M$44.4330.27

Summary

Mettler-Toledo International beats Bio-Rad Laboratories on 13 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Medpace?

Bio-Rad Laboratories (NYSE:BIO.B) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Medpace had 15 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 15 mentions for Medpace and 0 mentions for Bio-Rad Laboratories. Medpace's average media sentiment score of 1.26 beat Bio-Rad Laboratories' score of 0.00 indicating that Medpace is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Medpace Positive

Medpace has a net margin of 17.67% compared to Bio-Rad Laboratories' net margin of 8.59%. Medpace's return on equity of 110.15% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories8.59% 3.54% 2.48%
Medpace 17.67%110.15%24.84%

Bio-Rad Laboratories has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Bio-Rad Laboratories has higher revenue and earnings than Medpace. Medpace is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.78$759.90M$8.2544.25
Medpace$2.53B6.52$451.12M$17.0634.66

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Medpace has a consensus price target of $595.20, indicating a potential upside of 0.66%. Given Medpace's stronger consensus rating and higher possible upside, analysts plainly believe Medpace is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Medpace
0 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Medpace beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Revvity?

Bio-Rad Laboratories (NYSE:BIO.B) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Bio-Rad Laboratories has higher earnings, but lower revenue than Revvity. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.78$759.90M$8.2544.25
Revvity$2.86B5.09$241.20M$2.1062.02

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.9% of Revvity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bio-Rad Laboratories has a net margin of 8.59% compared to Revvity's net margin of 8.16%. Revvity's return on equity of 8.34% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories8.59% 3.54% 2.48%
Revvity 8.16%8.34%5.01%

Revvity has a consensus target price of $114.77, suggesting a potential downside of 11.88%. Given Revvity's stronger consensus rating and higher possible upside, analysts clearly believe Revvity is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Revvity
0 Sell rating(s)
13 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.24

Bio-Rad Laboratories has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Revvity has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

In the previous week, Revvity had 16 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 16 mentions for Revvity and 0 mentions for Bio-Rad Laboratories. Revvity's average media sentiment score of 0.97 beat Bio-Rad Laboratories' score of 0.00 indicating that Revvity is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Revvity Positive

Summary

Revvity beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Charles River Laboratories International?

Bio-Rad Laboratories (NYSE:BIO.B) and Charles River Laboratories International (NYSE:CRL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Bio-Rad Laboratories has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.78$759.90M$8.2544.25
Charles River Laboratories International$4.02B3.44-$144.34M-$4.85N/A

Bio-Rad Laboratories has a net margin of 8.59% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories8.59% 3.54% 2.48%
Charles River Laboratories International -5.96%15.75%6.51%

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Charles River Laboratories International had 9 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 9 mentions for Charles River Laboratories International and 0 mentions for Bio-Rad Laboratories. Charles River Laboratories International's average media sentiment score of 0.93 beat Bio-Rad Laboratories' score of 0.00 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Charles River Laboratories International Positive

Bio-Rad Laboratories has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Charles River Laboratories International has a consensus price target of $255.65, indicating a potential downside of 11.66%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts plainly believe Charles River Laboratories International is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Charles River Laboratories International
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69

Summary

Charles River Laboratories International beats Bio-Rad Laboratories on 10 of the 16 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIO.B vs. The Competition

Export
MetricBio-Rad LaboratoriesLife Sciences Tools & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$9.76B$9.94B$7.25B$23.65B
Dividend YieldN/A1.46%2.53%3.73%
P/E Ratio44.2552.01213.3525.43
Price / Sales3.78112.07625.0920.84
Price / Cash36.4326.8577.0833.54
Price / Book1.3635.9812.857.61
Net Income$759.90M$56.67B$3.49B$1.07B
7 Day PerformanceN/A-0.83%1.04%-0.05%
1 Month Performance8.33%3.96%5.52%-0.24%
1 Year Performance47.78%26.47%24.39%12.80%

Bio-Rad Laboratories Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIO.B
Bio-Rad Laboratories
N/A$365.08
flat		N/A+47.8%$9.76B$2.58B44.258,200
ILMN
Illumina
2.2639 of 5 stars		$218.95
-1.2%		$191.31
-12.6%		+123.4%$33.03B$4.34B40.808,650
MTD
Mettler-Toledo International
3.9363 of 5 stars		$1,357.25
+0.1%		$1,445.31
+6.5%		+4.4%$27.22B$4.03B30.5718,100
MEDP
Medpace
3.2705 of 5 stars		$592.55
-0.1%		$595.20
+0.4%		+22.6%$16.54B$2.53B34.736,200
RVTY
Revvity
3.5919 of 5 stars		$130.83
+0.2%		$114.77
-12.3%		+52.0%$14.60B$2.86B62.3011,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:BIO.B) was last updated on 9/5/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel